RNA interference drugs silence specific genes. Investigational drug silences the PLK1 gene involved in tumor growth. Most patients tolerated the drug well; some showed therapeutic benefit. WASHINGTON, D.C. — Early results from a phase I, first in-human study indicate that a potential new class...
Posted to
News
on Tue, Apr 9 2013
Filed under: Press Releases, Research, Treatment, Cancer, Media Materials, AACR, American Association for Cancer Research, meeting, Annual Meeting, AACR Annual Meeting 2013, 2013 Annual Meeting, phase I, RNA interference, Dr. Ramesh K. Ramanathan, RNAi
Statement calls for greater efforts in smoking cessation. Tobacco use should be evaluated as a confounding factor in clinical trials. Surveys show tobacco use is often not measured. WASHINGTON, D.C. — An American Association for Cancer Research (AACR) statement calls on the oncology community to...
Posted to
News
on Tue, Apr 9 2013
Filed under: Press Releases, Research, Treatment, Cancer, Media Materials, AACR, American Association for Cancer Research, tobacco, smoking, Clinical Cancer Research, policy statement, clinical trials, Annual Meeting, AACR Annual Meeting 2013, 2013 Annual Meeting, confounding factor
Cisplatin-resistant non-small cell lung cancer cells expressed high levels of hyperactivated PARP1. Cells succumbed to PARP inhibitors in vitro. PARP inhibitor slowed cisplatin-resistant tumor growth in mice. PHILADELPHIA — Poly (ADP-ribose) polymerase inhibitors may be a novel treatment strategy...
Posted to
News
on Wed, Apr 3 2013
Filed under: Press Releases, Research, Treatment, Cancer, Media Materials, AACR, lung cancer, American Association for Cancer Research, Cancer Research, journal, non-small cell lung cancer, NSCLC, cisplatin, PARP1, PARP inhibitor, cisplatin resistance, PAR, Dr. Guido Kroemer
Ganetespib killed ALK-driven NSCLC cell lines more effectively than crizotinib. Displayed greater antitumor activity and prolonged survival in a mouse model. Potential as a new option for treating ALK-dependent lung cancers. PHILADELPHIA — A drug that indirectly impairs the function of several...
Posted to
News
on Tue, Mar 26 2013
Filed under: Press Releases, Research, Treatment, Cancer, Media Materials, AACR, lung cancer, American Association for Cancer Research, Cancer Discovery, journal, non-small cell lung cancer, anaplastic lymphoma kinase, ALK, NSCLC, ganetespib, resistance, crizotinib, Dr. David Proia